155 related articles for article (PubMed ID: 22918166)
1. Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway.
Wang H; Chen Y; Fernandez-Del Castillo C; Yilmaz O; Deshpande V
Mod Pathol; 2013 Jan; 26(1):139-47. PubMed ID: 22918166
[TBL] [Abstract][Full Text] [Related]
2. HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.
Dailey DD; Anfinsen KP; Pfaff LE; Ehrhart EJ; Charles JB; Bønsdorff TB; Thamm DH; Powers BE; Jonasdottir TJ; Duval DL
BMC Vet Res; 2013 Jul; 9():130. PubMed ID: 23816051
[TBL] [Abstract][Full Text] [Related]
3. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
[TBL] [Abstract][Full Text] [Related]
4. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
[TBL] [Abstract][Full Text] [Related]
5. The expression of NeuroD and mASH1 in the gastroenteropancreatic neuroendocrine tumors.
Shida T; Furuya M; Kishimoto T; Nikaido T; Tanizawa T; Koda K; Oda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Nakatani Y; Miyazaki M
Mod Pathol; 2008 Nov; 21(11):1363-70. PubMed ID: 18587321
[TBL] [Abstract][Full Text] [Related]
6. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
Bellizzi AM
Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
[TBL] [Abstract][Full Text] [Related]
7. Lack of nuclear expression of hairy and enhancer of split-1 (HES1) in pancreatic endocrine tumors.
Johansson T; Lejonklou MH; Ekeblad S; Stålberg P; Skogseid B
Horm Metab Res; 2008 May; 40(5):354-9. PubMed ID: 18491256
[TBL] [Abstract][Full Text] [Related]
8. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
[TBL] [Abstract][Full Text] [Related]
9. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
10. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
Bi YL; Min M; Shen W; Liu Y
Tumour Biol; 2016 Nov; 37(11):15145-15155. PubMed ID: 27677287
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling of small intestinal neuroendocrine tumors identified pathways and gene networks linked to tumorigenesis and metastasis.
Wang Q; Yu C
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32496505
[TBL] [Abstract][Full Text] [Related]
12. Expression of Stem Cell-associated Marker HES77 in Rectal Neuroendocrine Tumors.
Jernman J; Hagström J; Mäenpää H; Välimäki MJ; Haapasalo H; Nilsson O; Fermér C; Haglund C; Arola J
Anticancer Res; 2015 Jul; 35(7):3767-72. PubMed ID: 26124320
[TBL] [Abstract][Full Text] [Related]
13. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
[TBL] [Abstract][Full Text] [Related]
14. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
15. Notch 1 tumor expression is lacking in highly proliferative pancreatic neuroendocrine tumors.
Krausch M; Kroepil F; Lehwald N; Lachenmayer A; Schott M; Anlauf M; Cupisti K; Knoefel WT; Raffel A
Endocrine; 2013 Aug; 44(1):182-6. PubMed ID: 23225326
[TBL] [Abstract][Full Text] [Related]
16. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors.
Durkin AJ; Bloomston M; Yeatman TJ; Gilbert-Barness E; Cojita D; Rosemurgy AS; Zervos EE
J Am Coll Surg; 2004 Nov; 199(5):724-31. PubMed ID: 15501112
[TBL] [Abstract][Full Text] [Related]
18. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Haynes CM; Sangoi AR; Pai RK
Cancer Cytopathol; 2011 Jun; 119(3):193-201. PubMed ID: 21328566
[TBL] [Abstract][Full Text] [Related]
19. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?
Grillo F; Valle L; Ferone D; Albertelli M; Brisigotti MP; Cittadini G; Vanoli A; Fiocca R; Mastracci L
Endocrine; 2017 Sep; 57(3):494-502. PubMed ID: 28726181
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
Bane AL; Pinnaduwage D; Colby S; Reedijk M; Egan SE; Bull SB; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2009 Sep; 117(1):183-91. PubMed ID: 18563556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
